CTNM - Company ID 0001855175
The table below shows Contineum Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q3 2026 | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $15.98M | $12.70M | $11.65M | $10.99M | $14.06M | $13.71M |
| SG&A |
Contineum Therapeutics, Inc. reported annual revenue of $0.00 for fiscal year 2024. That is down 100.0% from $50.00M in fiscal 2023. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $4.98M |
| $4.73M |
| $5.26M |
| $3.94M |
| $3.84M |
| $4.40M |
| Operating income | -$20.97M | -$17.43M | -$16.90M | -$14.93M | -$17.90M | -$18.11M |
| Income tax | - | - | - | - | - | - |
| Net income | -$18.70M | -$15.15M | -$14.46M | -$12.79M | -$16.04M | -$15.99M |
| EPS (diluted) | -$0.49 | -$0.40 | -$0.39 | -$0.45 | -$0.62 | -$0.62 |